Doximity (DOCS) Receives a Hold From Truist Financial
Doximity's Strong Q4 Performance and Positive Outlook Justify Buy Rating
Doximity Analyst Ratings
Analysts Conflicted on These Healthcare Names: Zimmer Biomet Holdings (ZBH), Doximity (DOCS) and Arvinas Holding Company (ARVN)
Doximity (DOCS) Hold Rating Maintained Amid Balanced Growth Prospects and Market Uncertainty
Hold Rating on Doximity Amid Slower Growth and Economic Uncertainty
Barclays Sticks to Its Hold Rating for Doximity (DOCS)
Truist Securities Adjusts Price Target on Doximity to $31 From $29 After 'Strong' Fiscal Q4 Results, Keeps Hold Rating
Analysts Offer Insights on Healthcare Companies: Koninklijke Philips (PHG), Doximity (DOCS) and R1 RCM (RCM)
Doximity's Strong Market Position Amidst Economic Headwinds: A Balanced Hold Recommendation
Doximity Analyst Ratings
JPMorgan Upgrades Doximity to Neutral Rating From Underweight, Price Target Is $25
Doximity Analyst Ratings
Doximity Analyst Ratings
Doximity Analyst Ratings
Doximity Analyst Ratings
Truist Securities Maintains Hold on Doximity, Raises Price Target to $29-Report Released on 8th February 2024
Doximity Analyst Ratings
Doximity Analyst Ratings
Doximity Growth Prospects and Buy Rating Endorsed Amid Economic Caution